Each year after the annual meeting of the American Society of Clinical Oncology (ASCO), the media is abuzz with reports on the latest cancer advances. The national nonprofit organization CancerCare has created a free guide for helping cancer patients understand how new findings might affect their treatment options.
Each year after the annual meeting of the American Society of Clinical Oncology (ASCO), the media is abuzz with reports on the latest cancer advances. The national nonprofit organization CancerCare has created a free guide for helping cancer patients understand how new findings might affect their treatment options.
CancerCare's Your Guide to the Latest Cancer Research and Treatments presents research highlights from the 2006 ASCO annual meeting, held last June in Atlanta. The meeting is the most comprehensive gathering of cancer specialists and experts from around the world, bringing together more than 25,000 health professionals from all disciplines.
"There is extensive media coverage of ASCO, but it's not easy for patients to sort through the information or understand how it might relate to their treatment plan," said Diane Blum, MSW, executive director of CancerCare. "CancerCare is proud to provide this free educational booklet to help people with cancer and their loved ones stay on top of the latest news and get the best treatment possible."
Booklet Series
Your Guide to the Latest Research and Treatments is part of the CancerCare Connect booklet series, which is widely read by patients and health-care professionals alike. Other new booklets in the series include Controlling Cancer Pain and Managing Rash and Other Skin Reactions to Targeted Treatments, which provide cancer patients with practical suggestions that can help control the side effects of their treatment.
All Connect booklets are free of charge and can be downloaded from CancerCare's website, www. cancercare.org, or ordered by calling 1-800-813-HOPE (4673).
Efficacy and Safety of Zolbetuximab in Gastric Cancer
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.